Application of sophocarpine to preparation of medicament for treating cardiovascular diseases caused by coxsackie virus B

A technology for dilated cardiomyopathy and sophocarpine, applied in the field of pharmacy, can solve problems such as poor drug treatment effect, and achieve the effects of abundant drug sources, reduced mortality, and easy preparation

Inactive Publication Date: 2013-05-08
RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] The purpose of the present invention is to provide a kind of application of sophocarpine in the preparation of the medicine for the treatment of Coxsackie B virus-induced diseases, and described sophocarpine or its pharmaceutically acceptable salt will solve the problem of treating Coxsackie B virus in the prior art. Viral dilated cardiomyopathy, viral hypertrophic cardiomyopathy, viral coronary arteritis, viral pericarditis, viral endocarditis, viral valvulitis, pneumonia, bronchitis, hepatitis, cerebral palsy caused by B virus Technical problems of ineffective drug therapy for inflammation, meningitis, pancreatitis, diabetes mellitus, epidemic myalgia, epidemic chest pain

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sophocarpine to preparation of medicament for treating cardiovascular diseases caused by coxsackie virus B
  • Application of sophocarpine to preparation of medicament for treating cardiovascular diseases caused by coxsackie virus B
  • Application of sophocarpine to preparation of medicament for treating cardiovascular diseases caused by coxsackie virus B

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] Embodiment 1 in vitro test

[0077] The cytopathic inhibition method was used to measure the toxicity and antiviral (CVB3m) effect of sophocarpine on vero cells, and to compare the results of sophocarpine and "positive drugs" (morpholineguanidine, ribavirin) on vero cells, proving that Sophocarpine is low toxicity and has obvious anti-CVB 3 m drug

[0078] One, the preparation method of three kinds of mother liquors of sophocarpine, morpholinidine, ribavirin

[0079] The sophocarpine is 100 mg / ml, and the mother solution is diluted to 1% drug concentration (10000 μg / ml) in calf serum-free RPMI-1640 culture solution, and stored in a sterile low temperature. The preparation method of morpholinoguanidine and ribavirin is the same as above.

[0080] (1) Determination of toxicity of three drugs to vero cells

[0081] The concentration of 1% sophocarpine injection was diluted with calf serum-free RPMI-1640 culture medium to different concentrations (serial dilution from 1...

Embodiment 2

[0121] Embodiment 2 in vivo test

[0122] (1) The research on anti-virus in mice by sophocarpine injection shows that it has low toxicity and obvious anti-CBV effect, and the mice in the treatment group can survive for more than 50 days. However, 100% of the control group without medication died within 8 days, indicating that sophocarpine could reduce the death rate of infected mice and prolong the survival period. Cells in various organs of the virus group were obviously necrotic with inflammatory cell infiltration. However, the heart, lung, liver, pancreas, brain, and skeletal muscle of the treatment group had no obvious pathological changes, so sophocarpine resisted CVB. 3 m, so that it has a significant therapeutic effect on the diseases of various organs caused by Coxsackie B.

[0123] (2) Cell pathogenic effect (CPE)

[0124] The cytopathic method (micro method) was used to measure the anti-CVB3m effect of sophocarpine on Vero cells in the viremia phase serum of Balb / c...

Embodiment 3

[0128] Example 3 Epidemic Myalgia and Chest Pain

[0129] Epidemic chest pain: All five types of Coxsackie virus B can cause muscle pain and weakness. The incubation period is 2 to 5 days, which can be extended to 2 weeks. The main manifestations are fever and paroxysmal myalgia, which can involve the skeletal muscles of the whole body. The chest and abdomen are more common, especially the diaphragm is most likely to be involved, often concurrent with aseptic meningitis. Chest pain varies in severity, and severe cases may even cause shock. Chest pain is worse when the chest muscles are active. Chest X-ray examination was unremarkable. Current treatment is with analgesics or with morphine and codeine. Relief occurs within a few days after treatment with analgesics. However, there may be repeated attacks in the future, and the main lesion is inflammation and necrosis of skeletal muscle cells. If the presence of CVB-RNA in the patient's blood WBC can be detected by PCR in ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of sophocarpine or pharmaceutical salts thereof to preparation of medicament for treating cardiovascular diseases caused by coxsackie virus B. The sophocarpine or pharmaceutical salts thereof can be used as medicaments for treating dilated cardiomyopathy, viral endocarditis, viral valvulitis, viral pericarditis, viral coronary arteritis and hypertrophic cardiomyopathy caused by the coxsackie virus B. According to the sophocarpine or pharmaceutical salts thereof, the cure rate can be improved, the death rate can be reduced; and the sophocarpine or pharmaceutical salts thereof have no obvious toxic effects of cells, simpleness and convenience for preparation and low cost and are suitable for industrial production; meanwhile, medical resources of the sophocarpine are abundant.

Description

[0001] This application is a divisional application with application number "200710047507.2", application date "October 26, 2007", and invention title "Application of Sophocarpine in the Preparation of Drugs for Treating Coxsackie B Virus-Induced Diseases". technical field [0002] The invention belongs to the field of pharmacy, and relates to a medical preparation, in particular to the application of sophocarpine, especially the application of sophocarpine in the preparation of medicines for treating diseases caused by Coxsackie B virus. Background technique [0003] Sophocarpine (sophocarpine) is an effective monomer extracted from the dry roots and ground parts of Sophora flavescens and Sophora flavescens of the leguminous family Sophora genus, and its molecular formula is C 15 h 22 ON 2 , melting point is 53-54 ℃, and its structural formula is (I): [0004] [0005] About sophocarpine against Coxsackie virus B (coxsackie virus B) and its medicine preparation have be...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4375
Inventor 陈曙霞
Owner RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap